Common pitfalls in nanotechnology: lessons learned from NCI's Nanotechnology Characterization Laboratory. - Wikidata - wikimedia - TriplyDB

Common pitfalls in nanotechnology: lessons learned from NCI's Nanotechnology Characterization Laboratory.

Common pitfalls in nanotechnology: lessons learned from NCI's Nanotechnology Characterization Laboratory.

http://www.wikidata.org/entity/Q36403660

about

Current understanding of interactions between nanoparticles and the immune system Nanotechnologies for biomedical science and translational medicine Techniques for physicochemical characterization of nanomaterials How should the completeness and quality of curated nanomaterial data be evaluated?An ISA-TAB-Nano based data collection framework to support data-driven modelling of nanotoxicology Pre-clinical immunotoxicity studies of nanotechnology-formulated drugs: Challenges, considerations and strategy The janus facet of nanomaterials Identification and avoidance of potential artifacts and misinterpretations in nanomaterial ecotoxicity measurements Hyperthermia using nanoparticles--Promises and pitfalls.Pharmacokinetic issues of imaging with nanoparticles: focusing on carbon nanotubes and quantum dots Transfer studies of polystyrene nanoparticles in the ex vivo human placenta perfusion model: key sources of artifacts High resolution characterization of engineered nanomaterial dispersions in complex media using tunable resistive pulse sensing technology Technology for Innovation in Radiation Oncology Provenance information as a tool for addressing engineered nanoparticle reproducibility challenges Targeting cancer cells in the tumor microenvironment: opportunities and challenges in combinatorial nanomedicine.Multifunctional RNA nanoparticles.Summary report of PQRI Workshop on Nanomaterial in Drug Products: current experience and management of potential risks.Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors.Nanoparticle-mediated delivery of a rapidly activatable prodrug of SN-38 for neuroblastoma therapy.Core-Crosslinked Polymeric Micelles: Principles, Preparation, Biomedical Applications and Clinical Translation Safe anticoagulation when heart and lungs are "on vacation".Reference materials and representative test materials to develop nanoparticle characterization methods: the NanoChOp project case Size, Stability, and Porosity of Mesoporous Nanoparticles Characterized with Light Scattering.Use of XPS to Quantify Thickness of Coatings on Nanoparticles.Surface characterization of nanomaterials and nanoparticles: Important needs and challenging opportunities.Real-time analysis of composite magnetic nanoparticle disassembly in vascular cells and biomimetic media.Methods for the In Vitro Characterization of Nanomedicines-Biological Component Interaction.Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines.Nanoparticles in drug delivery: mechanism of action, formulation and clinical application towards reduction in drug-associated nephrotoxicity.Nanosafety research--are we on the right track?Strategy for selecting nanotechnology carriers to overcome immunological and hematological toxicities challenging clinical translation of nucleic acid-based therapeutics.Development of Halofluorochromic Polymer Nanoassemblies for the Potential Detection of Liver Metastatic Colorectal Cancer Tumors Using Experimental and Computational Approaches.Polymer therapeutics at a crossroads? Finding the path for improved translation in the twenty-first century.Crossing the barrier: treatment of brain tumors using nanochain particles.Preparation, characterization, and in vitro dosimetry of dispersed, engineered nanomaterials.In vitro cytotoxicity of superparamagnetic iron oxide nanoparticles on neuronal and glial cells. Evaluation of nanoparticle interference with viability tests.Horizon scan of nanomedicinal products.Facilitating Translational Nanomedicine via Predictive Safety Assessment.Platinum nanoparticles in nanobiomedicine.Clofazimine encapsulation in nanoporous silica particles for the oral treatment of antibiotic-resistant Mycobacterium tuberculosis infections.

P2860

Q26345204-BDCCCC30-560A-4187-B0B3-8B6EADDE7371 Q26776376-97A5DF6F-7157-4629-AD01-362F0D8631C9 Q27009549-280BDC87-F768-4B21-B899-6B106FA3CCC3 Q27908490-61C9D910-5489-44E0-9934-57E1FC8E2565 Q27942681-CC9A1CED-5B85-4D87-A8A3-6A416F2D9D30 Q28081577-9BD89C85-5541-4F0C-A142-A56627B49FD8 Q28083583-B657DB77-BAB1-4D65-98C8-741E034320C0 Q28384347-58B588C2-24FE-4E2B-AC44-197F2480D353 Q28384618-3D826080-AC20-4619-A618-D2C4EC4AE96B Q28388580-AADB3BF0-A889-40C2-B473-E9B2BB65DAD9 Q28393082-1CB8E8ED-33AE-4D13-8464-A287FA64043A Q28394762-33A4D9A2-64FD-455A-A438-AE118BD17930 Q28610710-93F4BF99-113F-4938-85DE-6218690B0405 Q29048614-641FB6B1-6845-4590-9F9C-357EE12F5C41 Q30279055-96C9E497-B4D6-4B29-AAFA-5400A21F47A7 Q34306130-7EB91651-DC92-415A-AC00-4EAB50D5A86E Q34871881-5CB10CB2-4558-4616-B132-C30CCE58A14D Q35100986-13E62525-2B9F-421C-9FDB-241B0FA9B633 Q35182759-2646FC98-513A-4E9E-B777-24AC4C1D68A9 Q35438759-A08E18A1-02E8-498E-A3D6-656DCB367BF6 Q35625209-BE43E506-E8C7-475E-A0F8-C21734486D17 Q36174398-C5B65379-CC85-4AE8-A20A-B3AE2B1BD2BE Q36260671-89EF1311-91DB-43F7-A3F9-7334712EA41F Q37210878-A4C90FA3-7039-47FE-9145-11EF043847F6 Q37406394-0E30697F-1E89-43A1-B98C-77E1AAFB4F2D Q37659934-D0A1F8B6-A404-47D0-B7CC-CDBCFFFDA4B5 Q37731267-37550747-A512-4F8B-826A-8077021DC0FB Q38112504-F445E49F-A5EC-47CD-8F33-E17A0D0E7565 Q38233071-525DF30B-9CA9-415F-87D9-B26906CE154B Q38258828-DDFDEF4A-E021-4BE4-B941-C1E770B917C5 Q38494470-49B56D01-ACDF-4392-985E-FBEB9A4C5C3C Q38608740-808E479F-C568-4195-9FA9-CEC11F5B086B Q38645927-286BB91B-AF23-41B0-9FD8-91EAE7A9E535 Q38691508-BCC5EC9E-B336-4C9D-8F1E-542BADEC2DCA Q38720595-2FBC4200-32C0-491D-A7F6-DAB519E9BF61 Q38849195-FF445E1C-8D1C-4435-9C62-28B9DFC18D99 Q39037527-9041CA20-9F09-4AFE-A51C-7E7BCEFF6CAD Q39244552-0B664AA9-149A-4D86-9253-B24B9A0B26D4 Q39428343-7F12EB2A-8064-42B3-AA63-5AE89491DD04 Q40280093-E1526039-1E90-4478-B99D-0CAE1FB1CF49

P2860

Common pitfalls in nanotechnology: lessons learned from NCI's Nanotechnology Characterization Laboratory.

http://www.wikidata.org/entity/Q36403660

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

Common pitfalls in nanotechnol ...... y Characterization Laboratory.

@ast

Common pitfalls in nanotechnol ...... y Characterization Laboratory.

@en

type

label

Common pitfalls in nanotechnol ...... y Characterization Laboratory.

@ast

Common pitfalls in nanotechnol ...... y Characterization Laboratory.

@en

prefLabel

Common pitfalls in nanotechnol ...... y Characterization Laboratory.

@ast

Common pitfalls in nanotechnol ...... y Characterization Laboratory.

@en

P1433

Q36403660-38DA0BC7-CF42-4FF4-81BA-1FD12601AF21

P1476

Q36403660-ACC28B54-2973-4B89-A643-AB340412CDE7

P2093

Q36403660-0610542E-5289-4DFC-A580-39E44E456B1F

Q36403660-07AB1E95-6B95-4505-BFE0-EB6E99A3F1CD

Q36403660-22A92AA5-FFAC-4399-B10A-49DBA1AC1BBC

Q36403660-3704A84D-7F78-4F3C-A50B-E1C7611D9528

Q36403660-56C1389E-6D75-41A7-8466-9AB8C1A948E3

Q36403660-60BF8FE8-463C-4510-BACE-D51221A0B6B2

Q36403660-BBEC1915-A897-4EB1-BEB7-8EFE47067A1B

P2860

Q36403660-009A4DB4-AEC6-439F-B149-FB673B089BB3

Q36403660-0BC5AA04-8232-4AEA-BF7B-B203D1B94399

Q36403660-0F8743ED-4C2B-4F7F-844E-BAE8FEDA20AB

Q36403660-30293B23-471B-44A6-84FA-26110E536848

Q36403660-3B8AD791-731F-4103-830A-1A0E9D5DF860

Q36403660-555F17B1-96CF-42C5-9DDA-C8A15EFDCBB4

Q36403660-5BB430E1-0BF2-4C86-9233-914392985C87

Q36403660-5CB951F8-A654-413E-ACCB-7C044FF66C18

Q36403660-5F7948F5-CBB0-4585-BA56-6C85CA620852

Q36403660-7C7FA394-E0C6-4087-ADEA-B0C1AD8C653B

P304

Q36403660-0C800FFC-8B43-43C2-9756-8CC47B11F62A

P31

Q36403660-796F2D2C-94B0-4CF9-ACA0-BBCB03F517E9

P356

Q36403660-524635FD-EFC5-4113-853C-D2D5C653A3B2

P433

Q36403660-3CFC9E5A-2E0E-43F6-9969-2515B05422CB

P478

Q36403660-C9C43E4B-8CAF-46FF-BDD6-D145A93DECA2

P50

Q36403660-4725B5E8-F1D9-4FFD-8E52-668D19A84A6A

P577

Q36403660-94725C8E-1478-4A97-8A21-7A2159765D83

P5875

Q36403660-A8DF1734-B3F5-4D00-9B61-1BE2CD59973F

P698

Q36403660-E5907814-D6A2-420E-B4B0-36115BFE3B6E

P921

Q36403660-B7D232CE-6E26-45E3-A126-C65BF975845E

P932

Q36403660-857AC6E0-CA26-4380-B02D-A9682E5A2062

P356

P1433

Integrative Biology

P1476

Common pitfalls in nanotechnol ...... gy Characterization Laboratory

@en

P2093

Anil K Patri

http://www.w3.org/2001/XMLSchema#string

Jennifer Hall Grossman

http://www.w3.org/2001/XMLSchema#string

Marina A Dobrovolskaia

http://www.w3.org/2001/XMLSchema#string

Pavan P Adiseshaiah

http://www.w3.org/2001/XMLSchema#string

Rachael M Crist

http://www.w3.org/2001/XMLSchema#string

Scott E McNeil

http://www.w3.org/2001/XMLSchema#string

Stephan T Stern

http://www.w3.org/2001/XMLSchema#string

P2860

Manufactured nanomaterials (fullerenes, C60) induce oxidative stress in the brain of juvenile largemouth bass

Nickel and vanadium metal ions induce apoptosis of T-lymphocyte Jurkat cells.

Endotoxin removal from protein solutions.

Sterilization of Silver Nanoparticles Using Standard Gamma Irradiation Procedure Affects Particle Integrity and Biocompatibility.

Ambiguities in applying traditional Limulus amebocyte lysate tests to quantify endotoxin in nanoparticle formulations.

Nanoparticle albumin-bound paclitaxel: a novel Cremphor-EL-free formulation of paclitaxel.

Translational considerations for cancer nanomedicine.

Controlled release of biologically active silver from nanosilver surfaces.

Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2.

Dendrimer-based macromolecular MRI contrast agents: characteristics and application.

P304

66-73

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1039/C2IB20117H

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

Jeffrey D Clogston

P577

2013-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

228445254

http://www.w3.org/2001/XMLSchema#string

P698

22772974

http://www.w3.org/2001/XMLSchema#string

P921

P932

3499664

http://www.w3.org/2001/XMLSchema#string